These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 28027870)

  • 1. Novel triclabendazole prodrug: A highly water soluble alternative for the treatment of fasciolosis.
    Flores-Ramos M; Ibarra-Velarde F; Jung-Cook H; Hernández-Campos A; Vera-Montenegro Y; Castillo R
    Bioorg Med Chem Lett; 2017 Feb; 27(3):616-619. PubMed ID: 28027870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A highly water soluble benzimidazole derivative useful for the treatment of fasciolosis.
    Flores-Ramos M; Ibarra-Velarde F; Hernández-Campos A; Vera-Montenegro Y; Jung-Cook H; Cantó-Alarcón GJ; Del Rivero LM; Castillo R
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5814-5817. PubMed ID: 25455496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fosfatriclaben, a prodrug of triclabendazole: Preparation, stability, and fasciolicidal activity of three new intramuscular formulations.
    Flores-Ramos M; Leyva-Gómez G; Rojas-Campos T; Cruz-Mendoza I; Hernández-Campos A; Vera-Montenegro Y; Castillo R; Velázquez-Martínez I; Padierna-Mota C; Arias-García R; Ibarra-Velarde F
    Vet Parasitol; 2024 Apr; 327():110113. PubMed ID: 38232512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficiency comparison of experimental fosfatriclaben with three commercial fasciolicides in experimentally infected sheep.
    Arias-García R; Vera-Montenegro Y; Flores-Ramos M; Castillo R; Hernández-Campos A; Ibarra-Velarde F
    Parasitol Res; 2020 Aug; 119(8):2687-2693. PubMed ID: 32514648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and fasciolicidal activity of 5-chloro-2-methylthio-6-(1-naphthyloxy)-1H-benzimidazole.
    Hernández-Campos A; Ibarra-Velarde F; Vera-Montenegro Y; Rivera-Fernández N; Castillo R
    Chem Pharm Bull (Tokyo); 2002 May; 50(5):649-52. PubMed ID: 12036021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of an experimental injectable prodrug formulation against Fasciola hepatica of different ages in experimentally infected sheep.
    Rojas-Campos T; Ibarra-Velarde F; Vera-Montenegro Y; Flores-Ramos M; Cruz-Mendoza I; Leyva-Gómez G; Hernández-Campos A
    Vet Parasitol; 2021 Oct; 298():109524. PubMed ID: 34271317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Field study on the determination of the effective dose of injectable fosfatriclaben prodrug in sheep naturally infected with Fasciola hepatica.
    Ibarra-Velarde F; Rojas-Campos T; Vera-Montenegro Y; Flores-Ramos M; Castillo R; Leyva-Gómez G
    Parasitol Res; 2022 Jan; 121(1):433-440. PubMed ID: 34739596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increase of carboxylesterase activity in Fasciola hepatica recovered from triclabendazole treated sheep.
    Scarcella S; Miranda-Miranda E; Cossío-Bayúgar R; Ceballos L; Fernandez V; Solana H
    Mol Biochem Parasitol; 2012 Oct; 185(2):151-3. PubMed ID: 22814337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance of Fasciola hepatica against Triclabendazole in cattle in Cajamarca (Peru): a clinical trial and an in vivo efficacy test in sheep.
    Ortiz P; Scarcella S; Cerna C; Rosales C; Cabrera M; Guzmán M; Lamenza P; Solana H
    Vet Parasitol; 2013 Jul; 195(1-2):118-21. PubMed ID: 23352107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of two isolates of Fasciola hepatica to treatment with triclabendazole in vivo and in vitro.
    Walker SM; McKinstry B; Boray JC; Brennan GP; Trudgett A; Hoey EM; Fletcher H; Fairweather I
    Parasitol Res; 2004 Dec; 94(6):427-38. PubMed ID: 15517388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Characterization of a Phosphate Prodrug of Isoliquiritigenin.
    Boyapelly K; Bonin MA; Traboulsi H; Cloutier A; Phaneuf SC; Fortin D; Cantin AM; Richter MV; Marsault E
    J Nat Prod; 2017 Apr; 80(4):879-886. PubMed ID: 28252963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triclabendazole resistance involving Fasciola hepatica in sheep and goats during an outbreak in Almirante Tamandare, Paraná, Brazil.
    Oliveira DR; Ferreira DM; Stival CC; Romero F; Cavagnolli F; Kloss A; Araújo FB; Molento MB
    Rev Bras Parasitol Vet; 2008 Sep; 17 Suppl 1():149-53. PubMed ID: 20059835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Design of a Russian sample of the antifascioliasis antihelminthic triclabendazole and evaluation of its therapeutic efficiency].
    Mikhaĭlitsyn FS; Arkhipov IA; Eleev AB; Podushkin VIu; Sevbo DP
    Med Parazitol (Mosk); 2005; (4):38-9. PubMed ID: 16445238
    [No Abstract]   [Full Text] [Related]  

  • 14. A study of a restricted programme of strategic dosing against Fasciola hepatica with triclabendazole.
    Fawcett AR
    Vet Rec; 1990 Nov; 127(20):492-3. PubMed ID: 2275087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triclabendazole-resistant Fasciola hepatica in southwest Wales.
    Thomas I; Coles GC; Duffus K
    Vet Rec; 2000 Feb; 146(7):200. PubMed ID: 10718597
    [No Abstract]   [Full Text] [Related]  

  • 16. Diagnosis of triclabendazole resistance in Fasciola hepatica.
    Sargison N
    Vet Rec; 2012 Aug; 171(6):151-2. PubMed ID: 22890399
    [No Abstract]   [Full Text] [Related]  

  • 17. Tegumental surface changes in adult Fasciola hepatica in response to treatment in vivo with triclabendazole in the sheep host.
    Toner E; Brennan GP; Hanna RE; Edgar HW; Fairweather I
    Vet Parasitol; 2010 Sep; 172(3-4):238-48. PubMed ID: 20627418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of closantel and triclabendazole against Fasciola hepatica in experimentally infected sheep.
    Maes L; Vanparijs O; Lauwers H; Deckers W
    Vet Rec; 1990 Nov; 127(18):450-2. PubMed ID: 2275080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fasciola hepatica: histological changes in the reproductive structures of triclabendazole (TCBZ)-sensitive and TCBZ-resistant flukes after treatment in vivo with TCBZ and the related benzimidazole derivative, Compound Alpha.
    Hanna RE; Edgar HW; McConnell S; Toner E; McConville M; Brennan GP; Devine C; Flanagan A; Halferty L; Meaney M; Shaw L; Moffett D; McCoy M; Fairweather I
    Vet Parasitol; 2010 Mar; 168(3-4):240-54. PubMed ID: 20053501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tegumental surface changes in juvenile Fasciola hepatica in response to treatment in vivo with triclabendazole.
    Halferty L; Brennan GP; Hanna RE; Edgar HW; Meaney MM; McConville M; Trudgett A; Hoey L; Fairweather I
    Vet Parasitol; 2008 Aug; 155(1-2):49-58. PubMed ID: 18511199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.